Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction

Nephrology Dialysis Transplantation

Volumn 28, Issue 2, 2013, Pages 327-336

  Ko, Hung T ^a   Yin, Jian L ^a   Wyburn, Kate ^a   Wu, Huiling ^a   Eris, Josette M ^a   Hambly, Brett D ^a   Chadban, Steven J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

chronic allograft dysfunction; cyclosporin A; kidney transplantation; sirolimus; VEGF VEGFR

Indexed keywords

CYCLOSPORIN; MESSENGER RNA; RAPAMYCIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CELL PROLIFERATION; CELL STIMULATION; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS EPITHELIUM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LASER CAPTURE MICRODISSECTION; LEUKOCYTOSIS; MALE; MESANGIUM CELL; METABOLIC INHIBITION; MITOSIS INHIBITION; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEINURIA; RAT; RENOVASCULAR DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUBULOINTERSTITIAL FIBROSIS;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CYCLOSPORINE; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PODOCYTES; PROTEINURIA; RATS; RATS, INBRED F344; RATS, INBRED LEW; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874524346     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs453     Document Type: Article

References (42)

1. Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-961 (Pubitemid 38745595)
2. Oberbauer R, Segoloni G, Campistol JM et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18: 22-28 (Pubitemid 41742941)
3. Buchler M, Caillard S, Barbier S et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531 (Pubitemid 47561618)
4. Kreis H, Oberbauer R, Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817 (Pubitemid 38294812)
5. Vuiblet V, Birembaut P, Francois A et al. Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrol Dial Transplant 2012; 27: 411-416
6. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858 (Pubitemid 37025404)
7. Letavernier E, Pe'raldi MN, Pariente A et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198-1203 (Pubitemid 41746797)
8. Chapman JR, Rangan GK. Why do patients develop proteinuria with sirolimus? Do we have the answer? Am J Kidney Dis 2010; 55: 213-216
9. Franz S, Regeniter A, Hopfer H et al. Tubular toxicity in sirolimusand cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Am J Kidney Dis 2010; 55: 335-343
10. Biancone L, Bussolati B, Mazzucco G et al. Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy. Am J Transplant 2010; 10: 2270-2278
11. Vogelbacher R, Wittmann S, Braun A et al. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007; 84: 1492-1499 (Pubitemid 350294725)
12. Abraham RT, Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483-510 (Pubitemid 26130192)
13. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135 (Pubitemid 34155123)
14. Letavernier E, Bruneval P, Vandermeersch S et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009; 24: 630-638
15. Basu A, Contreras AG, Datta D et al. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res 2008; 68: 5689-5698
16. Molhoek KR, Griesemann H, Shu J et al. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 2008; 68: 4392-4397
17. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007; 2: 251-275 (Pubitemid 46448066)
18. Olsson AK, Dimberg A, Kreuger J et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371
19. Ozdemir BH, Ozdemir FN, Haberal N et al. Vascular endothelial growth factor expression and cyclosporine toxicity in renal allograft rejection. Am J Transplant 2005; 5: 766-774 (Pubitemid 40461286)
20. Malmstrom NK, Kallio EA, Rintala JM et al. Vascular endothelial growth factor in chronic rat allograft nephropathy. Transpl Immunol 2008; 19: 136-144
21. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676 (Pubitemid 36749215)
22. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF-a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007; 106: 32-37
23. Keedy VL, Sandler AB. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 2007; 98: 1825-1830 (Pubitemid 350002185)
24. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608 (Pubitemid 36800018)
25. Guan F, Villegas G, Teichman J et al. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 2006; 291: F422-F428 (Pubitemid 44148132)
26. Ballermann BJ. Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron Physiol 2007; 106: 19-25
27. Yin JL, Pilmore HL, Yan YQ et al. Expression of growth arrestspecific gene 6 and its receptors in a rat model of chronic renal transplant rejection. Transplantation 2002; 73: 657-660 (Pubitemid 34193634)
28. Boersema M, Rienstra H, van den Heuvel M et al. Donor and recipient contribution to transplant vasculopathy in chronic renal transplant dysfunction. Transplantation 2009; 88: 1386-1392
29. Patel S, Chung SH, White G et al. The "atheroprotective" mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques. Int J Cardiol 2010; 145: 183-187
30. Saleem MA, Ni L, Witherden I et al. Co-localization of nephrin, podocin, and the actin cytoskeleton: evidence for a role in podocyte foot process formation. Am J Pathol 2002; 161: 1459-1466
31. Kakizaki Y, Kraft N, Atkins RC. Differential control of mesangial cell proliferation by interferon-gamma. Clin Exp Immunol 1991; 85: 157-163
32. Yin JL, Shackel NA, Zekry A et al. Real-time reverse transcriptasepolymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol Cell Biol 2001; 79: 213-221 (Pubitemid 32522168)
33. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81: 643-654
34. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333 (Pubitemid 37509740)
35. Frost P, Shi Y, Hoang B et al. AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells. Oncogene 2007; 26: 2255-2262 (Pubitemid 46572812)
36. Reinders ME, Sho M, Izawa A et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112: 1655-1665 (Pubitemid 38063723)
37. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716 (Pubitemid 36278589)
38. Garovic VD, Wagner SJ, Petrovic LM et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007; 22: 1136-1143 (Pubitemid 46523429)
39. Coombes JD, Mreich E, Liddle C et al. Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 2005; 68: 2599-2607 (Pubitemid 43251006)
40. Keller K, Daniel C, Schocklmann H et al. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 2006; 21: 2724-2735 (Pubitemid 44542224)
41. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242
42. Shihab FS, Bennett WM, Isaac J et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity. Kidney Int 2003; 63: 522-533 (Pubitemid 36126798)